Nasopharyngeal Carcinoma
Conditions
Interventions
1:Neoadjuvant chemotherapy of lobaplatin combined with 5-FU, concurrent chemotherapy of lobaplatin and IMRT
Sponsors
Nasopharyngeal Carcinoma Department of Sun Yat-sen University Cancer Center
Eligibility
Sex/Gender
All
Age
18 Years to 60 Years
Inclusion criteria
Inclusion criteria: 1. Histologic diagnosis of nasopharyngeal carcinoma; 2. Aged between 18 60 years; 3. T3-4N0-1M0, T1-4N2-3M0 (UICC 7th edition); 4. KPS>=80; 5. No distant metastasis; 6. Laboratory parameters: Bone marrow function: WBC>=4.0*10^9/L, ANC>=1.5*10^9/L; PLT >=100*10^9/L; HB>=90g/L; Hepatic function: STB, CB<=ULN*1.5; ALT AST<=ULN*1.5; Renal function: Cr<=ULN; Coagulation function: PT INR)<=ULN*1.5; 7. Without the malignant tumor of other tissue(excluding cerical cancer, bal cell carcinoma or squamous carcinoma); 8. Without other anti-cancer therapy (including steroids); 9. Without other serious disease limitted in the trial; 10. Voluntary to participate sign informed consent document.
Exclusion criteria
Exclusion criteria: 1. Distant metastases; 2. Previously treated (surgery, chemotherapy, radiotherapy, EGFR targeted therapy or immunotherapy); 3. Second malignancy within 5 years; 4. Precious therapy with an investigational agent; 5. Uncontrolled seizure disorder or other serious neurologic disease; 6. Allergic reaction (>=Grade III) to any drug including in this study; 7. Clinically significant cardiac or respiratory disease; 8. Creatinine clearance <30ml/min; 9. Drug or alcohol addiction; 10. Do not have full capacity for civil acts; 11. With severe complications or active infection; 12. Concurrent immunotherapy or hormone therapy for other diseases; 13. Pregnancy or lactation.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Objective response rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| Progression-free survival;Overall survival;safety; | — |
Contacts
Public ContactGuo Xiang
Outcome results
None listed